Literature DB >> 21411592

Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens.

Sylvie Armand1, Pascale Vanhuls, Guy Delcroix, René Courcol, Nadine Lemaître.   

Abstract

The sensitivities of the Xpert MTB/RIF test and an in-house IS6110-based real-time PCR using TaqMan probes (IS6110-TaqMan assay) for the detection of Mycobacterium tuberculosis complex (MTBC) DNA were compared by use of 117 clinical specimens (97 culture positive and 20 culture negative for MTBC) that were frozen in sediment. The 97 clinical specimens included 60 respiratory and 37 nonrespiratory specimens distributed into 36 smear-positive and 61 smear-negative specimens. Among the 97 culture-positive specimens, 4 had rifampin-resistant isolates. Both methods were highly specific and exhibited excellent sensitivity (100%) with smear-positive specimens. The sensitivity of the Xpert MTB/RIF test with the whole smear-negative specimens was more reduced than that of the IS6110-TaqMan assay (48 versus 69%, P = 0.005). Both methods exhibited similar sensitivities with smear-negative respiratory specimens, but the Xpert MTB/RIF test had lower sensitivity with smear-negative nonrespiratory specimens than the IS6110-TaqMan assay (37 versus 71%, P = 0.013). Finally, the sensitivities of the Xpert MTB/RIF test and the IS6110-TaqMan assay were 79% and 84%, respectively, with respiratory specimens and 53% and 78%, respectively (P = 0.013), with nonrespiratory specimens. The Xpert MTB/RIF test correctly detected the rifampin resistance in smear-positive specimens but not in the one smear-negative specimen. The Xpert MTB/RIF test is a simple rapid method well adapted to a routine laboratory that appeared to be as sensitive as the IS6110-TaqMan assay with respiratory specimens but less sensitive with paucibacillary specimens, such as smear-negative nonrespiratory specimens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411592      PMCID: PMC3122654          DOI: 10.1128/JCM.02157-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Removal of PCR inhibitors by silica membranes: evaluating the Amplicor Mycobacterium tuberculosis kit.

Authors:  B Böddinghaus; T A Wichelhaus; V Brade; T Bittner
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria.

Authors:  G P KUBICA; W E DYE; M L COHN; G MIDDLEBROOK
Journal:  Am Rev Respir Dis       Date:  1963-05

3.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

Review 4.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 5.  Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis.

Authors:  S Greco; E Girardi; A Navarra; C Saltini
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

6.  Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting.

Authors:  Fabienne Laraque; Anne Griggs; Meredith Slopen; Sonal S Munsiff
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

Review 7.  Nucleic acid amplification tests for the diagnosis of tuberculous lymphadenitis: a systematic review.

Authors:  P Daley; S Thomas; M Pai
Journal:  Int J Tuberc Lung Dis       Date:  2007-11       Impact factor: 2.373

8.  Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Authors:  Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

9.  Comparison of methods of DNA extraction for real-time PCR in a model of pleural tuberculosis.

Authors:  Ana Santos; Rosa Cremades; Juan Carlos Rodríguez; Eduardo García-Pachón; Montserrat Ruiz; Gloria Royo
Journal:  APMIS       Date:  2010-01       Impact factor: 3.205

10.  In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression.

Authors:  Laura L Flores; Madhukar Pai; John M Colford; Lee W Riley
Journal:  BMC Microbiol       Date:  2005-10-03       Impact factor: 3.605

View more
  66 in total

1.  Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence.

Authors:  Raquel Moure; Rogelio Martín; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa.

Authors:  L E Scott; N Gous; B E Cunningham; B D Kana; O Perovic; L Erasmus; G J Coetzee; H Koornhof; W Stevens
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

3.  Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens.

Authors:  Arzu N Zeka; Sezai Tasbakan; Cengiz Cavusoglu
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

Review 4.  Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.

Authors:  Stephen D Lawn; Mark P Nicol
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

5.  A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Pamela Nabeta; Amy L Davidow; Viral Vadwai; Rasim Tahirli; Vanisha Munsamy; Mark Nicol; Martin Jones; David H Persing; Doris Hillemann; Sabine Ruesch-Gerdes; Felicity Leisegang; Carlos Zamudio; Camilla Rodrigues; Catharina C Boehme; Mark D Perkins; David Alland
Journal:  Am J Respir Crit Care Med       Date:  2011-11-01       Impact factor: 21.405

6.  Comparative Study of GeneXpert with ZN Stain and Culture in Samples of Suspected Pulmonary Tuberculosis.

Authors:  Monika Agrawal; Ashish Bajaj; Vinay Bhatia; Sarjana Dutt
Journal:  J Clin Diagn Res       Date:  2016-05-01

7.  Bronchial Wash Gene Xpert MTB/RIF in Lower Lung Field Tuberculosis: Sensitive, Superior, and Rapid in Comparison with Conventional Diagnostic Techniques.

Authors:  Shital Patil; Swati Narwade; Mazhar Mirza
Journal:  J Transl Int Med       Date:  2017-09-30

8.  Evaluation of the Xpert MTB/RIF Ultra Assay for Direct Detection of Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples.

Authors:  Daniel Perez-Risco; David Rodriguez-Temporal; Ivan Valledor-Sanchez; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

Review 9.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 10.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.